Dyadic International, Inc. ( DYAI) IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 December 9, 2025 9:30 AM EST Good day, and welcome to the iAcessAlpha Virtual Best Ideas winter ...
Revvity targets 2026 growth with multiomics, AI-powered base editing, NGS newborn screening, and immunotherapy advances.
To the research team working to save him, KJ Muldoon was first known only as Patient Eta. But within months, KJ’s name — and ...
A collaborative effort by the Formosa-Jordan lab from the Max Planck Institute for Plant Breeding Research in Cologne, ...
This year, gene-editing technology was customized to fix mutations in a single patient’s genes for the first time.
High-resolution imaging has revealed the internal layout of chromatin condensates, showing how DNA fibers fold and interact ...
First anthrax vaccine developed using recombinant DNA technology- Annual production capacity of up to 10 million doses at GC ...
Tuberculosis (TB) is one of the oldest and deadliest infectious diseases we know. It commonly impacts the lungs, but can also affect other areas of the body like the spine, brain or kidneys.
Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of ...
According to Research by SNS Insider, the U.S. Peptide Therapeutics Market is Set to Reach USD 35.71 Billion by 2032, Supported by Rising Adoption of Precision Biologics and Advances in Peptide ...
A Nobel laureate, he identified an enzyme that cuts DNA, laying the groundwork for milestones in scientific research and ...
The protein, reverse transcriptase, has become an essential tool for making DNA copies of RNA.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback